Metformin for Preventing Frailty in High-risk Older Adults
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Frailty is a geriatric syndrome which leads to poor health outcomes in older adults, such as
falls, disability, hospitalization, institutionalization, and death. Due to the dramatic
growth in the U.S. aging population and the health care costs associated with frailty
(estimated at more than $18 billion per year), frailty is a major health care problem. There
has been little research into potential pharmacologic interventions that would delay or
reduce the incidence of frailty. Thus, the major goal of this study is to test metformin as a
novel intervention for the prevention of frailty. The investigators propose that
diabetes/insulin resistance and inflammation are major contributors to frailty, and that the
use of metformin to modulate diabetes/insulin resistance and inflammation will prevent and/or
ameliorate the progression of frailty.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio